Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Using a nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate imatinib exposure (area under the curve, AU...

Descripción completa

Detalles Bibliográficos
Autores principales: Widmer, N, Decosterd, L A, Leyvraz, S, Duchosal, M A, Rosselet, A, Debiec-Rychter, M, Csajka, C, Biollaz, J, Buclin, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391118/
https://www.ncbi.nlm.nih.gov/pubmed/18475296
http://dx.doi.org/10.1038/sj.bjc.6604355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391118/
https://www.ncbi.nlm.nih.gov/pubmed/18475296
http://dx.doi.org/10.1038/sj.bjc.6604355

Ejemplares similares